What is in Mounjaro that causes weight loss — and how does the science work?

What tirzepatide actually is, and why two receptors matter more than one

Tirzepatide is a 39-amino-acid peptide, a lab-synthesised chain modelled on the body's own incretin hormones. When you eat, your gut releases GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1); both play roles in blood-sugar regulation, and both send signals that reduce appetite. Tirzepatide binds to the receptors for each of these hormones with high affinity, activating both pathways at once.

Why does that matter for weight? GLP-1 receptor activation alone reduces hunger and slows gastric emptying, that mechanism underpins semaglutide (Wegovy). GIP receptor activation appears to add a complementary effect, particularly on fat-cell signalling and on how the brain processes reward from food. Animal and human data suggest the dual action produces greater appetite suppression than either pathway alone, which is consistent with the larger average losses seen in head-to-head comparisons. You can read more about the precise downstream effects on the mechanism of Mounjaro's weight-loss effect page.

The NHS describes tirzepatide as working by slowing gastric emptying and increasing feelings of fullness, and its medicines page is a good place to confirm exactly how the drug is described for patients at a clinical level, see the NHS tirzepatide information page for the patient-facing summary.

What the SURMOUNT-1 trial found, and what it means in practice

The strongest evidence for tirzepatide's weight-loss effect comes from the SURMOUNT programme. SURMOUNT-1, published in the New England Journal of Medicine in 2022 and randomising 2,539 adults with obesity but without type 2 diabetes, found that participants receiving 15mg tirzepatide lost an average of around 20–21% of their body weight over 72 weeks, alongside a reduced-calorie diet and increased activity. Those on lower doses (5mg, 10mg) also lost meaningful weight, with averages of roughly 15–16% and 19–20% respectively.

NICE cited this evidence when it recommended tirzepatide (as Mounjaro) in December 2024. The committee's appraisal noted these were the largest average losses seen in a phase 3 weight-management trial at that point. A later head-to-head trial, SURMOUNT-5, found tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes.

There is an important nuance: these figures represent averages across trial populations. Individual results vary depending on adherence, starting weight, background health conditions and dose reached. Tirzepatide is not a uniform intervention, the results people experience on Mounjaro vary considerably, and that is expected from a medicine acting on complex biological pathways. The NICE appraisal is publicly accessible at NICE TA1026 for anyone wanting to read the committee's reasoning in full.

Beyond the receptor: how tirzepatide changes eating behaviour day to day

Understanding what tirzepatide contains is only part of the picture. What actually changes for people taking it are the downstream behavioural signals: reduced hunger between meals, earlier satiety during meals, and (for many) a reduced preoccupation with food that had previously felt involuntary. These are pharmacological effects, not willpower. Weight, for most people with obesity, is shaped by biology far more than behaviour in isolation.

Gastric slowing plays a large role here. When the stomach empties more slowly, blood-glucose rises more gradually after eating, insulin release is modulated, and the sense of fullness persists longer. This is why nausea is the most commonly reported side effect, particularly in the early weeks and after dose increases: the same mechanism that reduces appetite can also cause discomfort if food intake doesn't adjust alongside it. Most people find this settles as the body adapts, though anyone experiencing significant or persistent symptoms should speak to their prescriber rather than adjust doses independently.

It is worth building one small habit early: check that the pen you're using is stored in the fridge (2–8°C) and has not been left at room temperature beyond the window stated in the Patient Information Leaflet. The leaflet is the definitive guide to storage; reading it takes under a minute and catches the most common administration errors. For a broader picture of what else tirzepatide can affect beyond weight, the full effects of Mounjaro page covers the complete profile. If you're still establishing whether tirzepatide is the right fit, the BMI and eligibility criteria for Mounjaro explains the licensed thresholds in detail.

The licensed context: what tirzepatide is and isn't approved for

In the UK, tirzepatide (Mounjaro) carries a licence for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. It also holds a separate licence for type 2 diabetes management. Tirzepatide is not approved for cosmetic weight loss or short-term body-composition changes, the MHRA has been explicit that GLP-1 medicines are not assessed for those purposes.

It carries a Black Triangle (▼) designation, meaning it is subject to additional monitoring by the MHRA as a relatively new medicine. This doesn't mean it is unsafe; it means that any new or unexpected effects reported by patients and clinicians are reviewed with particular attention. Patients can contribute to that process by reporting suspected side effects at the MHRA Yellow Card scheme.

Tirzepatide is sometimes confused with semaglutide-based medicines. The tirzepatide and Mounjaro page clarifies the naming, and the broader tirzepatide overview covers the full clinical context. If you want to understand how private treatment works in practice, our Mounjaro treatment page explains the process, and our clinical team reviews every consultation personally before any prescription is issued. When you're ready, you can speak to our prescribers through a free consultation with no obligation to proceed.